Common genetic aberrations such as gain in the ETS-related gene (ERG), loss of phosphatase and tensin homolog (PTEN), mutations in either tumor protein p53 (TP53) or ataxia telangiectasia mutated (serine/threonine kinase (ATM)) are assessed to determine the PCa patient’s prognosis and lethality [5]. This evidence concerns the gene TP53 and posterior cortical atrophy.